Evidence map›Paper›PMID 42104480›Full record

GuidelineJournal of hematology & oncology2026

Chinese guidelines for HER2-targeted therapy in gastric and gastroesophageal junction adenocarcinoma (2025 Edition).

Xiaotian Zhang, Yakun Wang, Muyan Cai, Fenghua Wang, Tong Xie, Jianming Ying, Weiqi Sheng, Xiangshan Fan, Xiujuan Qu, Chang Wang and 13 more

Abstract readPractice Guideline
PubMed Full text at PMC Publisher
In one paragraph

Guideline in Journal of hematology & oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors.

Xiaotian Zhang *State Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers, Beijing Key Laboratory of Carcinogenesis and Translational Research, Department of Gastrointestinal Oncology, Peking University Cancer Hospital & Institute, Beijing, 100142, China.
Yakun Wang *State Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers, Beijing Key Laboratory of Carcinogenesis and Translational Research, Department of Gastrointestinal Oncology, Peking University Cancer Hospital & Institute, Beijing, 100142, China.
Muyan Cai *Department of Medical Oncology, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-Sen University Cancer Center, Sun Yat-Sen University, Guangzhou, 510060, China.
Fenghua Wang *Department of Medical Oncology, Sun Yat-Sen University Cancer Center, Guangzhou, 510030, China.
Tong Xie *Department of Gastrointestinal Oncology, Peking University Cancer Hospital and Institute, Beijing, 100142, China.
Jianming YingDepartment of Pathology, National Cancer Center / National Clinical Research Center for Cancer / Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, 100021, China.
Weiqi ShengDepartment of Pathology, Fudan University Shanghai Cancer Center, Shanghai, 200032, China.
Xiangshan FanDepartment of Pathology, the First Affiliated Hospital of Anhui Medical University, Hefei, 230022, China.
Xiujuan QuDepartment of Medical Oncology, the First Hospital of China Medical University, Shenyang, 110001, China.
Chang WangDepartment of Medical Oncology, the First Hospital of China Medical University, Shenyang, 110001, China.
Zhi PengState Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers, Beijing Key Laboratory of Carcinogenesis and Translational Research, Department of Gastrointestinal Oncology, Peking University Cancer Hospital & Institute, Beijing, 100142, China.
Jie'er YingDepartment of Medical Oncology, Zhejiang Cancer Hospital, Hangzhou, 310022, China.
Miaozhen QiuDepartment of Medical Oncology, Sun Yat-Sen University Cancer Center, Guangzhou, 510030, China.
Tianshu LiuDepartment of Medical Oncology, Zhongshan Hospital Fudan University, Shanghai, 200032, China.
Yueping LiuDepartment of Pathology, the Fourth Hospital of Hebei Medical University, Shijiazhuang, 050000, China.
Dongmei LinState Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers, Beijing Key Laboratory of Carcinogenesis and Translational Research, Department of Gastrointestinal Oncology, Peking University Cancer Hospital & Institute, Beijing, 100142, China.
Xiaohong YaoInstitute of Pathology and Southwest Cancer Center, Southwest Hospital, Third Military Medical University, Chongqing, 400038, China.
Ziyu LiKey Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Gastrointestinal Cancer Center, Peking University Cancer Hospital & Institute, Beijing, 100142, China.
Wenlong GuanDepartment of Medical Oncology, Sun Yat-Sen University Cancer Center, Guangzhou, 510030, China.
Ruihua XuDepartment of Medical Oncology, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-Sen University Cancer Center, Sun Yat-Sen University, Guangzhou, 510060, China. xurh@sysucc.org.cn.
Jin LiDepartment of Medical Oncology, Shanghai East Hospital, School of Medicine, Tongji University, Shanghai, 200120, China. lijin@csco.org.cn.
Hong BuDepartment of Pathology, Institute of Clinical Pathology, Key Lab of Transplant Engineering and Immunology, Ministry of Health, West China Hospital, Sichuan University, Chengdu, 610041, China. hongbu@scu.edu.cn.
Lin ShenState Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers, Beijing Key Laboratory of Carcinogenesis and Translational Research, Department of Early Drug Development Center, Peking University Cancer Hospital & Institute, Beijing, 100142, China. shenlin@bjmu.edu.cn.

Funding

Beijing Hospitals Authority's Ascent Plan DFL20241104Beijing Xisike Clinical Oncology Research Foundation Y-2022HER2AZQN-0080Noncommunicable Chronic Diseases-National Science and Technology Major Project 2024ZD0520600
6 · The paper itself

Abstract

Gastric and gastroesophageal junction adenocarcinoma (GC/GEJC) poses a substantial clinical burden in China. This updated guideline introduces a refined human epidermal growth factor receptor 2 (HER2) classification system (high, intermediate, low, absent) to redefine patient stratification for targeted therapy. It integrates cutting-edge evidence on standardized detection-including immunohistochemistry, in situ hybridization, and liquid biopsy-to overcome spatial-temporal heterogeneity. Recent progress in the use of HER2-targeted agents, including monoclonal antibodies, antibody-drug conjugates, tyrosine kinase inhibitors, and bispecific antibodies, is systematically reviewed and presented to inform evidence-based clinical practice. These updates aim to optimize personalized HER2-targeted therapy and improve outcomes in GC/GEJC patients.

Indexed as

AdenocarcinomaErb-b2 Receptor Tyrosine KinasesEsophageal NeoplasmsEsophagogastric JunctionStomach NeoplasmsChinaHumansMolecular Targeted TherapyERBB2 protein, humanErb-b2 Receptor Tyrosine KinasesDiagnosisGastric cancerGuidelineHER2Treatment

Identifiers

PMID42104480
PMCPMC13308193

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.